Courtney D. DiNardo,


Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Courtney D. DiNardo, MD, MSCE, is an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston. She is an academic clinical researcher with a primary focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics for molecularly defined patient subgroups.  

Dr DiNardo has experience with designing, overseeing, and executing successful clinical trials, from phase 1 dose-finding studies, to innovative investigator-initiated phase 2 trials, to confirmatory randomized phase 3 trials. She has served an integral role in several highly influential trials involving IDH1, IDH2, and BCL-2 inhibitors, which have led to the US Food and Drug Administration approvals of 3 therapies for acute myeloid leukemia since 2017 (ie, the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL-2 inhibitor venetoclax in combination with hypomethylating agents).


Oncology / MDS & AML

Perspectives on Newly Diagnosed MDS

expert roundtables by Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; and Rami S. Komrokji, MD

In the treatment of patients with newly diagnosed myelodysplastic syndrome (MDS), there are opportunities for risk stratification, prognostication,...READ MORE